Repligen Corp (RGEN) Stock
Key stats
- Market cap
- $11.03B
- Price / Earnings ratio
- -942.2x
- EPS (TTM)
- -$0.20
- Volume
- Loading
- 52-week high
- $198.87
- 52-week low
- $100.99
Source: third-party data provider, as of November 13, 2026
Compare with RGEN
Recent news
What Repligen (RGEN) Said on Its Q3 Earnings Call
What Repligen (RGEN) Said on Its Q3 Earnings Call
RGEN
Repligen (RGEN) Q3 Earnings and Revenues Surpass Estimates
Repligen (RGEN) Q3 Earnings and Revenues Surpass Estimates
RGEN
BioLife Solutions Shareholders Approve Repligen Merger Agreement
BioLife Solutions Shareholders Approve Repligen Merger Agreement
RGEN
Why Did KOD, RGEN, BIIB Stocks Rise To 52-Week Highs?
Why Did KOD, RGEN, BIIB Stocks Rise To 52-Week Highs?
RGENNews tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 46.56
- MACD 12/26/9
- -0.94
- EMA 9 of MACD
- -0.26
- MACD histogram
- -0.68
- SMA 50
- $177.31
- Price below SMA 50
- EMA 50
- $174.63
- Price below EMA 50
- SMA 200
- $145.18
- Price above SMA 200
- EMA 200
- $155.88
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $0.53 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news
What Repligen (RGEN) Said on Its Q3 Earnings Call
What Repligen (RGEN) Said on Its Q3 Earnings Call
RGENRepligen (RGEN) Q3 Earnings and Revenues Surpass Estimates
Repligen (RGEN) Q3 Earnings and Revenues Surpass Estimates
RGENBioLife Solutions Shareholders Approve Repligen Merger Agreement
BioLife Solutions Shareholders Approve Repligen Merger Agreement
RGENWhy Did KOD, RGEN, BIIB Stocks Rise To 52-Week Highs?
Why Did KOD, RGEN, BIIB Stocks Rise To 52-Week Highs?
RGEN
BioLife Solutions Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of BioLife Solutions, Inc. - BLFS
BioLife Solutions Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of BioLife Solutions, Inc. - BLFS
RGEN
Why Is Repligen (RGEN) Up 27.7% Since Last Earnings Report?
Why Is Repligen (RGEN) Up 27.7% Since Last Earnings Report?
RGEN
Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen
Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen
RGEN
5 Biotech Stocks Worth Adding to Your Portfolio Now
5 Biotech Stocks Worth Adding to Your Portfolio Now
RGEN
Cancer Vaccine Breakthrough Lifts 5 Biotech Names. Here's Who's Best Positioned.
Cancer Vaccine Breakthrough Lifts 5 Biotech Names. Here's Who's Best Positioned.
RGEN
These Two Biotech Stocks Recorded Fresh Milestones Today – What’s Driving Today’s Gains?
These Two Biotech Stocks Recorded Fresh Milestones Today – What’s Driving Today’s Gains?
RGENNews tone: automated (AI) classification of the article's content, not a price prediction.
About Repligen Corp
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Olivier Loeillot | President, CEO & Director | 1970 |
| Mr. Jason K. Garland | CFO & Chief Compliance Officer | 1974 |
| Mr. James R. Bylund | Chief Operating Officer | 1963 |
| Mr. Anthony J. Hunt | Advisor | 1964 |
| Mr. Ralf Kuriyel | Senior Vice President of Research & Development | 1958 |
| Mr. Brian Douglass | Senior VP & Chief Product Officer | 1975 |
| Ms. Violetta Hughes | Chief Accounting Officer | 1973 |
| Ms. Heather Ems | Chief Information Officer | — |
| Mr. Jacob K. Johnson C.F.A. | Vice President of Investor Relations | — |
| Mr. George A Scott Jr., J.D., M.B.A. | Senior VP & General Counsel | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 46.56
- MACD 12/26/9
- -0.94
- EMA 9 of MACD
- -0.26
- MACD histogram
- -0.68
- SMA 50
- $177.31
- Price below SMA 50
- EMA 50
- $174.63
- Price below EMA 50
- SMA 200
- $145.18
- Price above SMA 200
- EMA 200
- $155.88
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $180.00
- Average
- $201.67
- High
- $225.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +9.6 | -4.3 | ||||||||||
| 2022 | -23.1 | -3.1 | -3.1 | -16.4 | +3.6 | -2.6 | +28.1 | +3.2 | -12.5 | -7.8 | -3.6 | -10.0 |
| 2023 | +14.4 | -8.6 | -4.5 | -7.2 | +9.4 | -15.3 | +20.8 | +4.1 | -9.5 | -13.2 | +19.6 | +9.0 |
| 2024 | +5.6 | +0.7 | -5.9 | -10.2 | -5.9 | -16.2 | +35.7 | -8.9 | +5.0 | -7.9 | +8.6 | -4.3 |
| 2025 | +16.2 | -0.4 | -18.1 | +7.4 | -13.9 | +4.9 | -7.4 | +2.9 | +10.8 | +2.2 | +13.9 | -1.5 |
| 2026 | -9.1 | -14.8 | -5.7 | -0.0 | +5.8 | +10.8 | +1.5 | +23.1 | +13.1 | -0.2 | -0.2 |
